Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results deaths Eclinical improvement Edeath or ventilation E

COVID-19 severe or critically meta-analysis

CAPSID, 2021
 
NCT04433910
RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallysome concern
53/52 inconclusive -15% 52%
INSPIRATION, 2021
 
NCT04486508
RCTanticoagulation, intermediate prophylactic dosecontrolCOVID-19 severe or criticallysome concern
276/286 inconclusive 8%
INSPIRATION, 2021
 
NCT04486508
RCTanticoagulation, intermediate prophylactic doseanticoagulant, prophylactic doseCOVID-19 severe or criticallysome concern
276/286 inconclusive 8%
O’Donnell, 2021
 
NCT04359810
RCTconvalescent plasma treatmentplaceboCOVID-19 severe or criticallylow
150/73 inconclusive -48% 18%
RECOVER, 2021
 
EudCT 2020-001632-10
RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallylow
43/47 inconclusive 8%
REMAP-CAP plasma, 2021
 
NCT02735707
RCTconvalescent plasma treatmentcontrolCOVID-19 severe or criticallylow
1095/916 safety concern -4%
REMAP-CAP tocilizumab, 2021
 
NCT02735707
RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
353/402 conclusif -27% demonstrated58%
REMAP-CAP, ACTIV-4a, ATTACC, critically ill patients, 2021
 
NCT02735707
RCTanticoagulant, curative dosecontrolCOVID-19 severe or criticallysome concern
591/616 inconclusive 7% -15%
REMAP-CAP, ACTIV-4a, ATTACC, critically ill patients, 2021
 
NCT02735707
RCTanticoagulant, curative doseanticoagulant, prophylactic doseCOVID-19 severe or criticallysome concern
591/616 inconclusive 7% -15%
Rosas (REMDACTA), 2021
 
NCT04409262
RCTtocilizumab placeboCOVID-19 severe or criticallysome concern
434/215 inconclusive -5% -2%
Sekine (PLACOVID), 2021
 
NCT04547660
RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallysome concern
80/80 inconclusive 34% -5%
Talaschian, 2021
 
IRCT20081027001411N4
RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
20/20 inconclusive 23%
Veiga, 2021
 
NCT04403685
RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
65/64 safety concern safety concern153% 49%
AlQahtani, 2020
 
NCT04356534
RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallysome concern
20/20 inconclusive -47%
CAP-China (Wang et al.), 2020
 
NCT04257656
RCTremdesivirplaceboCOVID-19 severe or criticallylow
158/79 inconclusive 9% 21%
CORIMUNO-TOCI-1 (Group 1), 2020
 
NCT04331808
RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
64/67 inconclusive -7% -39%
CORIMUNO-TOCI-ICU (Group 2), 2020
 
NCT04331808
RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
49/43 inconclusive -32%
COVACTA (Rosas), 2020
 
NCT04320615
RCTtocilizumab placeboCOVID-19 severe or criticallysome concern
301/151 safety concern 25% 17%
Li, 2020
 
ChiCTR2000029757
RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallysome concern
52/51 inconclusive -37% 36%
PlasmAr, 2020
 
NCT04344535
RCTconvalescent plasma treatmentcontrolCOVID-19 severe or criticallylow
228/106 inconclusive -6% -17%
PlasmAr, 2020
 
NCT04344535
RCTconvalescent plasma treatmentplaceboCOVID-19 severe or criticallylow
228/106 inconclusive -6% -17%
22 studies excluded by filtering options (7 RCT / 15 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).